

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



March 16, 2021

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE Code: SUNPHARMA

BSE Limited
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001
BSE Code: 524715

Dear Sirs/ Madam,

Sub: Proceedings of National Company Law Tribunal (“NCLT”) Convened meetings of the Unsecured Creditors and of the Equity Shareholders of Sun Pharmaceutical Industries Limited (“the Company”) held on March 16, 2021.

Pursuant to the order dated January 07, 2021, passed by the Hon’ble NCLT, Ahmedabad Bench, the separate meetings of unsecured creditors and equity shareholders of the Company were held through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”) in compliance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India from time to time, on Tuesday, March 16, 2021 at 02:00 p.m. IST and 03:15 p.m. IST respectively (collectively referred to as “Meetings”), for approving the Scheme of Amalgamation and Merger of Sun Pharma Global FZE (“Transferor Company”) with Sun Pharmaceutical Industries Limited (“Transferee Company”), and their respective members and creditors.

Mr. Gautam Doshi, an Independent Director of the Transferee Company, appointed as the Chairman of the Meetings by Hon’ble NCLT, chaired the Meetings. Mr. Gaurang Parikh, an Independent Chartered Accountant and alternate Chairman of the Meetings, as appointed by the Hon’ble NCLT in absence of Mr. Gautam Doshi, was also present through Video-Conferencing.

In addition to Mr. Gautam Doshi, following Directors of the Company, attended the:

- (i) meeting of the unsecured creditors’ of the Company - Mr. Israel Makov, Mr. Dilip Shanghvi, Mr. Sailesh T. Desai, Mr. Kalyanasundaram Subramanian and Ms. Rekha Sethi.

Mr. Sudhir V. Valia and Mr. Vivek Chaand Sehgal could not attend the meeting due to their prior commitments and/or occupancy with urgent work.

- (ii) meeting of the equity shareholders of the Company - Mr. Israel Makov, Mr. Dilip Shanghvi, Mr. Sailesh T. Desai, Mr. Kalyanasundaram Subramanian, Mr. Sudhir V. Valia and Ms. Rekha Sethi

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



Mr. Vivek Chaand Sehgal could not attend the meeting due to his prior commitments and/or occupancy with urgent work.

The requisite quorum was present at the Meetings. The Chairman at the Meetings inter alia explained the implication and objectives of the Scheme of Amalgamation and Merger of Sun Pharma Global FZE (“Transferor Company”) with Sun Pharmaceutical Industries Limited (“Transferee Company”), and their respective members and creditors.

Representatives, from S R B C & Co. LLP, Statutory Auditors of the Company, and from KJB & Co LLP, Secretarial Auditors of the Company had also joined the Meetings through Video Conferencing.

Mr. Chintan J. Goswami, Partner of KJB & Co. LLP (AAM-3002), Practicing Company Secretaries, Mumbai, appointed by Hon’ble NCLT, was the Scrutinizer for the remote e-voting and votes cast through electronic voting system during the Meetings. He had joined the Meetings through Video-Conferencing.

In case of equity shareholders’ meeting, in compliance with Hon’ble NCLT Order dated January 07, 2021, read with the provisions of Section 230(4), Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, the Company had provided the facility to the equity shareholders of the Company to cast their votes either by way of remote e-voting facility during the period commencing from Saturday, March 13, 2021 at 9:00 a.m. IST and ending on Monday, March 15, 2021 at 5:00 p.m. IST (inclusive of both the days) and the facility of electronic voting system was provided during the meeting hours. The said facility was made available to the shareholders till 15 minutes from the conclusion of the Meeting.

In case of unsecured creditors’ meeting, in compliance with Hon’ble NCLT Order dated January 07, 2021, the Company had provided the facility of electronic voting during the meeting hours. The said facility was made available to the unsecured creditors till 15 minutes from the conclusion of the Meeting.

Members who had registered themselves as speakers for the equity shareholders’ meeting, raised queries pertaining to certain matters which were suitably replied by Mr. Dilip Shanghvi, Managing Director of the Company. There were no unsecured creditors who had registered themselves as speakers.

The Chairman at the respective Meetings had requested the Scrutinizer to complete the scrutinizing process and submit the report to him/ person authorized by him.

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



The Chairman then stated that the results along with Scrutinizer's Report on the e-voting done during the meeting of the unsecured creditors and Scrutinizer's Consolidated Report on the e-voting done during the meeting of the equity shareholders' and voting done through remote e-voting will be submitted to the stock exchanges within 48 hours of the conclusion of the respective Meetings and will also be placed on the website of the Company and Central Depository Services (India) Limited (the agency appointed for providing e-voting facility). The results will also be displayed on the notice board of the Company at its registered office and corporate office.

We would like to inform you that the resolutions for the approval of Scheme of Amalgamation and merger are approved by the equity shareholders and by the unsecured creditors of the Company at respective Meetings with requisite majority.

As per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the detailed results of voting for the resolution proposed at the meeting of the equity shareholders will be intimated separately.

We request you to kindly take note of the same.

Thanking You,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

Ashok I. Bhuta
Sr. GM - Secretarial &
Compliance Officer